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effect can be masked by the autocrine
production of SCF.
Finally, we evaluated the effects of two
KIT inhibitors, imatinib (Carvajal et al.,
2011) and sorafenib (Heinrich et al., 2012)
on the signaling pathways activated in
KIT-N505I expressing cells. Sorafenib,
and imatinib to a lesser extent, inhibited
SCF-induced KIT autophosphorylation as
well as ERK and AKT phosphorylations in
these cells (Figure 2d). Therefore, the KIT-
N505I mutation did not abolish the sensi-
tivity of KIT to these inhibitors.
To conclude, we described a new
KIT-N505I mutation in an acral lentiginous
melanoma that confers the receptor
an increased basal activity, associated
with exacerbated signaling properties.
The respective roles of mutation and over-
expression of KIT in the acquisition of
tumorigenic properties by these melanoma
cells remain to be elucidated. Never-
theless, patients with melanoma bearing
the KIT-N505I mutation might be eligible
for treatment with imatinib or sorafenib.
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TO THE EDITOR
Accumulating evidence suggests auto-
phagy, the principle catabolic process
for lysosomal degradation of surplus
macromolecules (Roy and Debnath,
2010), is fundamental to tumorigenesis.
Impaired autophagy results in accumu-
lation of cellular breakdown products,
increased oxidative stress and neoplastic
transformation (Mathew et al., 2009);
whilst efficient autophagy facilitates
metastatic tumor survival through
sustained metabolic activity (Roy and
Debnath, 2010). Consequently, theAccepted article preview online 22 November 2013; published online 19 December 2013
Abbreviations: AJCC, American Joint Committee on Cancer; DFS, disease-free survival; MSM, melanoma-
specific mortality
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currently accepted view is that auto-
phagy suppresses growth early in tumor
development but promotes tumor
survival at later stages (Garber, 2011).
p62 (also known as sequestosome-1/
SQSTM1) is a multidomain adaptor
protein transporting ubiquitinated pro-
teins during autophagy (Moscat and
Diaz-Meco, 2009); as such, p62 plays
a role in selective autophagic degra-
dation of a number of substrates
(Ichimura and Komatsu, 2010; Komatsu
and Ichimura, 2010). Normally, p62 is
broken down along with its cargo with-
in the autophagolysosome. However,
impaired autophagy is accompanied
by p62 accumulation, resulting in large
p62/ubiquitinated protein aggregates
(Komatsu and Ichimura, 2010); a pro-
cess thought to be a key factor in
tumorigenesis (Moscat and Diaz-Meco,
2009).
The present biomarker discovery
study aimed to define immunohisto-
chemical p62 expression as a prognostic
biomarker in a retrospective cohort
comprising 29 melanocytic nevi and
121 primary cutaneous melanomas
(Supplementary Methods online and
Supplementary Table S1 online). In
keeping with the ‘‘autophagy paradox,’’
we hypothesized p62 levels would
be elevated in melanoma compared
to nevi, with the highest levels detec-
ted in early stage disease where condi-
tions represent a pro-tumorigenic
environment.
Comparison of median p62 expression
levels between nevi and all melanomas
revealed a significant increase in expres-
sion levels in melanoma (14.82%) com-
pared to nevi (0.51%; Mann–Whitney
U, Po0.0001) (Figure 1a), and a step-
wise increase in median p62 expression
levels with localized tumor development
(0.51% in nevi to 44.5% in AJCC
(American Joint Committee on Cancer)
II disease, Mann–Whitney Po0.0001)
(Figure 1b). A relative decrease in med-
ian p62 expression (to 10.25%) was then
observed in primary tumors from patients
with metastatic stage III/IV disease
(stage II vs. stage III/IV Mann–Whitney
P¼ 0.005) (Figure 1b). This biphasic
expression in primary melanomas thus
mirrors the ‘‘autophagy paradox’’.
To determine the efficacy of p62
expression levels at identifying high-risk
tumors at diagnosis, comparison of
localized and metastatic disease (even-
tual AJCC stages I/II vs. stages III/IV)
revealed significantly lower median
p62 expression in the metastatic cohort
(10.25 vs. 26.94% in AJCC I/II; Mann–
Whitney, P¼ 0.016). p62 levels were
visibly bimodal, with a Wilcoxon
signed-rank test confirming that 20%
expression was an appropriate cut-point
for undertaking survival curve analysis,
and as such statistical modeling was
based on tumor p62 expression above
(‘‘high p62’’) or below 20% (‘‘low
p62’’).
Univariate analysis in all tumors was
used to assess disease outcome over a
7-year follow-up period and revealed a
modest, yet statistically significant, red-
uction in disease-free survival (DFS) in
patients with ‘‘low p62’’ tumors (40.9%
of patients in the ‘‘low p62’’ group
developed metastases compared to
21.8% in ‘‘high p62’’ tumors (log-rank
(Mantel–Cox) test P¼ 0.03, hazard ratio
(HR) 1.66 (95% confidence interval (CI)
1.03–2.69))) (Figure 2a).
Comparable univariate analysis of
melanoma-specific mortality (MSM) in
the whole melanoma cohort revealed a
nonsignificant trend towards an increa-
sed MSM in patients with ‘‘low p62’’
tumors (MSM 24.24% ‘‘low p62’’
tumors, vs. 14.55% in ‘‘high p62’’
tumors (log-rank (Mantel–Cox) test
P¼ 0.18, HR 1.5 (95% CI 0.83–2.74))).
Univariate analysis of other pre-hypothe-
sized risk factors for disease progression
were calculated (Supplementary
Methods online and Supplementary
Table S2 online); as expected there was
a significant increased risk of metastases
with increasing Breslow depth and tumor
ulceration in line with AJCC staging
criteria (Balch et al., 2009).
Univariate analysis of tumors pre-stra-
tified to AJCC stage II at diagnosis
revealed low p62 expression levels that
were associated with a trend for
worse DFS; with 67.74% of patients
in the ‘‘low p62’’ cohort developing
a metastasis within 7 years compared
to only 39.13% in the ‘‘high p62’’
group (log-rank (Mantel–Cox) test
P¼0.06, HR 1.7 (95% CI 0.97–2.96))
(Figure 2b). A similar trend was seen in
AJCC stage I disease, (log-rank (Mantel–
Cox) test P¼ 0.38, HR 1.53 (95% CI
0.58–4.09)).
MSM followed an identical trend with
‘‘low p62’’ AJCC stage II tumors result-
ing in a higher mortality rate compared
to ‘‘high p62’’ AJCC II tumors (MSM
35.48 vs. 21.74% respectively (log-rank
(Mantel–Cox) test P¼ 0.27, HR 1.51
(95% CI 0.72–3.2))).
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Figure 1. p62 expression in melanoma is consistent with the ‘‘autophagy paradox’’ in cancer. (a) Median
p62 expression levels were significantly higher in melanoma compared to benign melanocytic nevi
(Mann–Whitney U, Po0.0001). Horizontal lines represent median expression levels. (b) Median p62
expression levels increased between benign nevi and localized melanoma (eventual AJCC stages I and II),
but revealed a relative fall in metastatic disease (eventual AJCC stages III and IV) (Kruskal–Wallis
Po0.0001). Horizontal lines represent median expression levels. AJCC, American Joint Committee on
Cancer.
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Comparison of mean p62 expression
revealed no association with Breslow
depth or tumor ulceration (Supplemen-
tary Figure S1 online) and Cox propor-
tional hazards analysis undertaken to
assess whether the predictive effects of
p62 may be partially attributable to
covariates (Supplementary Methods
online and Supplementary Table S3
online) further supported p62 expression
levels as an independent stratifying prog-
nostic variable (Po9E 7), representing
biologically distinct processes to those
included in AJCC staging alone.
As a marker of autophagic activity,
the p62 status of the current melanoma
cohort fits with the ‘‘autophagy para-
dox’’; with the highest levels of p62
expression found in early, localized
disease (AJCC stages I and II) in keeping
with pro-tumorigenic dysfunctional
autophagy. However, tumor cells with
increased levels of autophagic activity
(either through reactivation or retention
of this function following tumorigenesis)
are more likely to metastasize by har-
nessing pro-survival autophagy.
Independently of its role in auto-
phagy, p62 expression may be regulated
by other signaling mechanisms inclu-
ding via NF-kB activation and interac-
tion with TRAF6 and caspase-8 (Mathew
et al., 2009; Komatsu and Ichimura,
2010). Therefore, the differential expre-
ssion of p62 within different AJCC stages
of melanoma cannot be assumed to result
entirely from impaired autophagic
activity. Nevertheless, results from the
present study add to the growing body
of evidence supporting the introduc-
tion of autophagy inhibitors to chemo-
therapeutic regimes in melanoma, stage I
trials of which are currently underway
(Komatsu et al., 2007), for which p62
expression will likely provide a useful
stratification criterion. Crucially however,
p62 represents a potential candidate
biomarker that may provide additional
prognostic information to AJCC disease
stage. Further validation in an indepen-
dent retrospective and ongoing prospec-
tive cohort will determine the prognostic
significance and effect size of p62 and its
application as a biomarker for refining
personalized therapies, ultimately transla-
ting into improved clinical outcome for
melanoma patients.
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Figure 2. p62 as a potential prognostic biomarker in melanoma. (a) Univariate analysis of p62 expression
revealed a significantly increased risk of metastasis in tumors expressing o20% p62 compared to tumors
expressing 420% p62 (log-rank (Mantel–Cox) test P¼0.03, HR 1.66 (95% CI 1.03–2.69)). (b) Analysis of
p62 expression levels after initial stratification by AJCC stage of disease reveals a suggestive increased risk
of metastasis in AJCC stage II primary tumors with p62 expressiono20% compared to tumors expressing
420% p62 (log-rank (Mantel–Cox) test P¼ 0.06, HR 1.70 (95% CI 0.97–2.96)). The number of patients
remaining at risk at 20-month intervals is stated below the x axis. AJCC, American Joint Committee on
Cancer; CI, confidence interval; HR, hazard ratio.
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